Supplement: Fox Chase Cancer Center

Fox Chase Cancer Center "I strongly believe that there will be a totally different way to treat cancer patients in the next 10 years," declared Michael V. Seiden, MD, PhD, shortly after he became president and CEO of Fox Chase Cancer Center in June 2007. "I think tumors will be removed and analyzed in a much more molecularly-based way. This is already being done at the research level, but in 10 years, therapies will be selected for people based on the molecula


Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

"I strongly believe that there will be a totally different way to treat cancer patients in the next 10 years," declared Michael V. Seiden, MD, PhD, shortly after he became president and CEO of Fox Chase Cancer Center in June 2007. "I think tumors will be removed and analyzed in a much more molecularly-based way. This is already being done at the research level, but in 10 years, therapies will be selected for people based on the molecular characterization of their tumors and how those therapies are working will be dissected in a much more sophisticated way, using techniques like molecular imaging."

Fox Chase's leader sets forth a bold challenge--one he thinks Fox Chase is uniquely positioned to meet. Its scientists and physicians conduct basic laboratory, clinical, translational, population and behavioral studies. Combining research in many disciplines with patient care enables Fox Chase to translate new research findings into medical ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here
3D illustration of a gold lipid nanoparticle with pink nucleic acid inside of it. Purple and teal spikes stick out from the lipid bilayer representing polyethylene glycol.
February 2025, Issue 1

A Nanoparticle Delivery System for Gene Therapy

A reimagined lipid vehicle for nucleic acids could overcome the limitations of current vectors.

View this Issue
Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

sartorius logo
Considerations for Cell-Based Assays in Immuno-Oncology Research

Considerations for Cell-Based Assays in Immuno-Oncology Research

Lonza
An illustration of animal and tree silhouettes.

From Water Bears to Grizzly Bears: Unusual Animal Models

Taconic Biosciences
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo

Products

Photo of a researcher overseeing large scale production processes in a laboratory.

Scaling Lentiviral Vector Manufacturing for Optimal Productivity

Thermo Fisher Logo
Discover a serum-free way to produce dendritic cells and macrophages for cell therapy applications.

Optimizing In Vitro Production of Monocyte-Derived Dendritic Cells and Macrophages

Thermo Fisher Logo
Collage-style urban graphic of wastewater surveillance and treatment

Putting Pathogens to the Test with Wastewater Surveillance

An illustration of an mRNA molecule in front of a multicolored background.

Generating High-Quality mRNA for In Vivo Delivery with Lipid Nanoparticles

Thermo Fisher Logo